Some 20 million people are diagnosed with Alzheimer’s disease every year around the globe – a figure that is expected to triple over the next three decades.
Alzheimer’s is the most common cause of dementia and researchers have spent a century trying to crack the enigma of finding effective treatments, 甚至可能是一种治疗方法, 治疗这种严重的退行性脑部疾病.
值得庆幸的是，一些重要的突破即将出现. 乐博彩票官方app处于科学发现的前沿.
哥德堡主办了久负盛名的大会
哥德堡, 乐博彩票官方app第二大城市, 主办2023年版AD/PD™会议. This is one of the world’s most prestigious international meetings on Alzheimer’s and Parkinson’s diseases.
为期五天的活动于3月28日开幕，H.M. 乐博彩票官方app的西尔维娅女王，她在阿尔茨海默氏症领域非常活跃和支持.
"Alzheimer’s disease has a devastating impact not only on patients but also families and caregivers. 除了这, the societal costs are huge and are estimated to be USD 500-600 billion per year in the US alone, 哪里有600多万人患有这种疾病,马丁Jönsson说, 乐博彩票官方appAlzeCure制药公司的首席执行官.
他的制药公司, 在乐博彩票官方app上市的公司, is one of several Swedish pioneers currently making promising progress on Alzheimer’s research, 药物和治疗发展.
“Our collaborative work in 乐博彩票官方app is laser focused on trying to counteract the early onset stage of Alzheimer’s. This means preventing the brain from degenerating in the first place,” Jönsson continues.
乐博彩票官方app在生物标志物研究和开发方面处于领先地位.抗体治疗新的重要里程碑
2023年1月6日.S. Food and Drug Administration (FDA) approved the drug LEQEMBI™ which was initially developed by the Swedish biopharma company BioArctic.
遵循随机临床试验, the medication has demonstrated a significant reduction in amyloid beta plaque in patients receiving treatment.
比利·邓恩，M.D., Director of the Office of Neuroscience in the FDA’s Center for Drug Evaluation and Research, commented in a press release: “This treatment option is the latest therapy to target and affect the underlying disease process of Alzheimer’s, 而不是只治疗疾病的症状.”
根据Martin Jönsson, 这只是乐博彩票官方app阿尔茨海默氏症研发管线中最近的里程碑之一.
他的公司AlzeCure Pharma有两个正在开发的平台，Alzstatin和NeuroRestore. A third Swedish company – Alzinova – has developed a candidate vaccine which has successfully passed pre-clinical trials.
A host of Swedish newcomers are also pioneering the use of AI and digital tools for monitoring and diagnostics.
“乐博彩票官方app在生物标志物方面确实处于领先地位. 这些发现是由哥德堡大学的研究人员做出的, 乌普萨拉大学(Uppsala University)和卡罗林斯卡学院(Karolinska Institute)可谓是开创性的,Jönsson指出.
他强调了Kaj Blennow教授的开创性工作, Lars Lannfelt和Bengt Winblad，他们都是该领域的国际知名人士. 更重要的是，新一代的年轻有才华的研究人员正在继续他们的遗产.
“At the conference in Gothenburg we will reveal exciting data together with Professor Henrik Zetterberg to highlight new advances with a potential preventive treatment, Alzstatin.”
乐博彩票官方app在有效治疗阿尔茨海默病方面处于领先地位有三个原因
那么乐博彩票官方app在对抗阿尔茨海默氏症方面相对成功的秘诀是什么呢?
That’s the question we put to Martin Jönsson in the run up to the AD/PD™ International Conference. 在他看来，这一切都归结为三个关键因素:
1. 世界领先的学术成就
Swedish researchers have over decades helped to shape the world’s understanding of how Alzheimer’s disease emerges and evolves.
A good example is Professor Lars Lannfelt’s success in the 1990s with his seminal discoveries in genetic mutations that cause early onset Alzheimer’s. The first became known as “the Swedish mutation” and the second one “the Arctic mutation”.
2. 开创生命科学领域
Large companies such as Astra Zeneca and Pharmacia paved the way for knowledge building around neurodegenerative diseases and helped to support therapy development. 这为进一步的发现创造了温床. The legacy was continued by a new generation of startups and researchers working closely together.
3. 风险承受风险的风险投资
乐博彩票官方app在动员私营部门资本方面取得了成功. 和研究人员一起, investors have been driven by a passion to solve one of the healthcare sector’s most elusive challenges.
The Swedish Alzheimer's Foundation (Alzheimerfonden) was established in 1988 and became a catalyst for numerous projects and initiatives.
“乐博彩票官方app’s progress on Alzheimer’s is owed to a shared feeling of being on an important mission to improve people’s lives in old age. 没有任何利己主义. 学术界合作, companies and investors has been instrumental to the breakthroughs we are witnessing today,Martin Jönsson总结道.
阅读更多关于乐博彩票官方app生命科学生态系统的信息 在这里.
